|To: keokalani'nui who wrote (98)||10/8/2002 8:00:50 PM|
|From: Miljenko Zuanic|
|<<In fact, ß3 knockout and ß3/ß5 double knockout mice demonstrate enhanced tumor angiogenesis, an effect that may be due to compensatory upregulation of the vascular endothelial growth factor receptor II in these animals (12).>>|
One target and candidate less, as it appears.
I am wandering WHY there is no SINGLE person who believe and have confidence in DiscoverWorks? :(
|RecommendKeepReplyMark as Last ReadRead Replies (1)|
|To: Miljenko Zuanic who wrote (99)||10/24/2002 10:44:03 AM|
|3-Dimensional Pharmaceuticals Reports Financial Results for the Third Quarter 2002|
Thursday October 24, 7:31 am ET
YARDLEY, Pa., Oct. 24 /PRNewswire-FirstCall/ -- 3-Dimensional Pharmaceuticals, Inc. (Nasdaq: DDDP - News; 3DP), a drug discovery and development company, today reported its financial results for the third quarter and nine months ended September 30, 2002.
Revenue for the third quarter was $5.5 million, compared to $5.8 million for the third quarter of 2001. Net loss for the quarter was $7.7 million, or $0.34 per share, compared to a net loss of $5.0 million, or $0.23 per share, for the third quarter of 2001. For the nine months ended September 30, 2002, revenues were $18.2 million, which was the same for the comparable period in 2001. Net loss for the nine months ended September 30, 2002 was $23.7 million, or $1.06 per share, compared to a net loss of $9.7 million, or $0.45 per share, for same period in 2001. Included in the results for the nine months ended September 30, 2002 was a non-cash in-process research and development charge of $4.1 million related to the acquisition of the pre-IND compound, 3DP-3534. 3DP ended the third quarter of 2002 with $75.1 million in cash, cash equivalents and marketable securities.
Including the $18.2 million recognized during the first nine months, 3DP's existing collaborations are estimated to provide revenue in 2002 of approximately $24.0 million, relating to up-front fees, research funding payments and license fees. 3DP's collaboration with Bristol-Myers Squibb Company, which commenced in July of 2000 and provides three years of research and development funding, was the largest source of revenue for the three and nine months ended September 30, 2002 and the comparative period in 2001.
Research and development expenses increased by $1.4 million to $9.7 million for the third quarter of 2002, compared to $8.3 million for the same period in 2001. Research and development expenses increased by $6.9 million to $27.8 million for the nine months ended September 30, 2002, compared to $20.9 million for the same period in 2001.
"3DP-3534, our compound for the prevention and treatment of thrombocytopenia, or low blood platelet count, has been undergoing extensive pre-clinical development activities and remains on track to begin Phase I human trials during the first half of 2003," said David C. U'Prichard, Ph.D., Chief Executive Officer of 3DP. "We continue to focus on building shareholder value while managing our cash burn."
3DP (http://www.3dp.com) is an integrated bio-pharmaceuticals company dedicated to revolutionizing small molecule drug discovery and development. 3DP's proprietary platform, DiscoverWorks®, has the potential to produce drug candidates suitable for faster development, with fewer resources and a higher probability of success than using conventional drug discovery methods. 3DP is developing its own drug pipeline and collaborates with other pharmaceutical companies in discovery and development.
|RecommendKeepReplyMark as Last ReadRead Replies (1)|
|To: mopgcw who wrote (102)||10/28/2002 8:10:24 PM|
|From: Miljenko Zuanic|
|Once opportunity, now maybe slipping away.|
Press Release Source: AstraZeneca LP
AstraZeneca's Investigational Oral Anticoagulant Exanta(TM) (ximelagatran) Reduced Risk of Blood Clots Following Orthopedic Surgery By 63 Percent Compared to Enoxaparin in Clinical Trial
Monday October 28, 8:09 am ET
WILMINGTON, Del., Oct. 28 /PRNewswire-FirstCall/ -- Results of a Phase III clinical trial of AstraZeneca's investigational oral anticoagulant EXANTA(TM) (ximelagatran) showed that treatment with EXANTA significantly reduced by 63 percent the risk of proximal deep vein thrombosis (DVT) and pulmonary embolism (PE) after orthopedic surgery compared with the low-molecular-weight heparin, enoxaparin (2.3 percent vs 6.3 percent, p=0.0000018). Results of EXPRESS (EXpanded PRophylaxis Evaluation Surgery Study), were presented at the 17th International Congress on Thrombosis meeting in Bologna, Italy.
In addition, treatment with EXANTA showed a 67 percent risk reduction (1.8 percent vs. 5.5 percent, p=0.00009) for total hip replacement (THR) and a 60 percent risk reduction (3.3 percent vs. 8.2 percent, p=0.006) for total knee replacement (TKR). EXPRESS also showed a 23.6 percent reduction in the risk of total DVT/PE following preventative treatment (thromboprophylaxis) with EXANTA, compared with enoxaparin (20.3 percent vs. 26.6 percent, p=0.0003).
EXPRESS was a randomized, double-blind, double-dummy study that included nearly 2,800 patients undergoing either total knee replacement or total hip replacement surgery in 12 European countries and South Africa. In the study, 1,377 patients received EXANTA, and 1,387 received enoxaparin. Study treatment was given for 8-11 days with bilateral venography performed on the final day of treatment.
The objective of the study was to compare the efficacy and safety of subcutaneous melagatran (2 mg immediately before surgery and 3 mg the evening after surgery) followed by the oral prodrug ximelagatran (24 mg twice daily) with once-daily injections of enoxaparin (40 mg) started the evening before surgery for the prevention of DVT/PE following total knee or hip replacement surgery.
There were no fatal or critical-site bleeding events in either group. Excessive bleeding at the operative site, as judged by the investigator was more common in the group receiving EXANTA than the group receiving enoxaparin (3 percent vs. 1.2 percent).
Each year in the United States, approximately 300,000 people experience symptomatic deep vein thrombosis (DVT), a commonly occurring condition where a clot forms in the deep veins, usually in the leg, impeding, or even blocking, blood flow. Many conditions predispose patients to DVT, and patients undergoing the more than 600,000 hip or knee replacement surgeries in the United States each year are a group at highest risk of developing DVT.
If a section of a clot in a patient with DVT breaks off, it may travel through the blood stream to the lungs and lodge in a pulmonary artery. This is known as pulmonary embolism (PE), a serious condition that can cause death. PE remains the most common preventable cause of death in hospital patients and causes up to 20 percent of early deaths after hip surgery.
EXANTA is the first oral direct thrombin inhibitor under Phase III investigation and the first investigational oral anticoagulant to reach Phase III in more than 50 years. The intended mechanism of action of EXANTA is to inhibit the activity of an enzyme called thrombin, which is critical to the final step in the formation of blood clots. Ongoing clinical studies with EXANTA utilize a fixed dose without routine coagulation monitoring.
AstraZeneca submitted a filing for a European license for EXANTA on July 24, 2002 for the prevention of DVT/PE in major elective orthopedic surgery. This was the first regulatory submission for EXANTA. In the United States, the parallel Phase III clinical trial program in orthopedic surgery, EXULT, remains on schedule.
AstraZeneca (NYSE: AZN - News) is a major international healthcare business engaged in the research, development, manufacture and marketing of ethical (prescription) pharmaceuticals and the supply of healthcare services. It is one of the top five pharmaceutical companies in the world with healthcare sales of over $16.4 billion and leading positions in sales of cardiovascular, gastrointestinal, oncology, anesthesia (including pain management), central nervous system (CNS) and respiratory products. In the United States, AstraZeneca is an $8.7 billion healthcare business with more than 10,000 employees.
For more information about AstraZeneca please visit astrazeneca-us.com.
This press release contains forward-looking statements with respect to AstraZeneca's business. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially. For a discussion of those risks and uncertainties, please see the company's Annual Report/Form 20-F for 2001.
Make Your Opinion Count - Click Here
|RecommendKeepReplyMark as Last ReadRead Replies (2)|